Search the Newsreel

Jiangxi Tungsten Rare and Precious Equipment在拟议收购中调整了业绩目标

Can Arafura Rare Earths (ASX:ARU) Turn Focus Into Traction?

(RARE) Risk Channels and Responsive Allocation

This article analyzes Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) using AI models, indicating weak sentiment across all horizons which supports a short bias. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional …

Ultragenyx Pharmaceutical, Inc. Revenue Breakdown – BX:UP0

Ultragenyx Pharmaceutical, Inc. (UP0) generated 533.53 million CHF in revenue last year, primarily from its Novel Products segment. The company's largest regional contribution came from North America, accounting for 298.87 million CHF. This financial overview highlights the company's key revenue drivers and geographical performance.

Vanguard Portfolio Management (RARE) discloses 6.85M-share Ultragenyx stake on 13G/A

Vanguard Portfolio Management LLC, along with affiliates, has reported a beneficial ownership of 6,853,427 shares of Ultragenyx Pharmaceutical Inc. common stock as of June 30, 2026. This stake represents 6.95% of the outstanding class, with Vanguard holding sole voting power over 63,292 shares and …

Did Lynas’ Zero-Coupon Convertible Bond Issue Reshape Lynas Rare Earths’ (ASX:LYC) Funding Risk-Reward Profile?

Ultragenyx Pharmaceutical Inc (RARE) Institutional Confidence

Ultragenyx Pharmaceutical Inc (RARE) has an institutional shareholding score of 10.00, ranking 1st in the Pharmaceuticals industry. The institutional shareholding proportion increased by 3.72% quarter-over-quarter, reaching 107.82%. Frank Sands is the largest institutional shareholder, holding 3.28% of outstanding shares.

Vanguard Capital Management (RARE) discloses 5.13% Ultragenyx ownership on Schedule 13G

Vanguard Capital Management has reported a 5.13% beneficial ownership stake in Ultragenyx Pharmaceutical Inc., according to a Schedule 13G filing. This amounts to 5,058,419 shares, with Vanguard holding sole voting power over 761,928 shares and sole dispositive power over all 5,058,419 shares. The filing …

AR3’s Koppamurra PFS marks landmark quarter and new rare earths discovery

BlackRock (RARE holder) discloses 8.3% Ultragenyx stake in amended 13G

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.3% beneficial ownership stake in Ultragenyx Pharmaceutical Inc., totaling 8,141,384 shares. BlackRock primarily holds sole voting and dispositive power over these shares, with no single underlying client exceeding a 5% interest. This filing indicates …

Is Lynas Rare Earths (ASX:LYC) Cheap Following Its Zero Coupon Convertible Bond Offer?

Ultragenyx Pharmaceutical Number of Employees 2026 | Employee Count & Headcount Data

Ultragenyx Pharmaceutical (NASDAQ: RARE) had approximately 1,285 employees worldwide as of March 2026, marking a 3.3% decline from 2023. The company, headquartered in Novato, California, is actively hiring despite a 128.1% decline in active job postings from the previous year. Most of its workforce …

Ultragenyx in the spotlight as earnings test growth comeback

Ultragenyx Pharmaceutical Inc. is set to announce its second-quarter earnings, with investors keenly observing whether the rare disease biotech can recover from a prior disappointment and validate analyst optimism. Analysts expect a loss of $1.23 per share on $182.1 million in revenue, which would …

Ultragenyx Pharmaceutical Inc (RARE) Financial Health: Profitability & Balance Sheet Analysis

Ultragenyx Pharmaceutical Inc (RARE) has a weak financial status with a score of 7.23, ranking 121 out of 155 in the Pharmaceuticals industry, although its operating efficiency is high. The company's latest quarterly revenue decreased by 2.36% year-over-year to $136.00M, and net profit saw …

2 Rare-Earth Stocks to Buy Right Now, and 1 to Sell

Key Points China dominates rare-earth extraction and processing, creating a major supply-chain vulnerability for the U.S. The U.S. is investing heavily in domestic rare-earth mining, processing, and "mine-to-magnet" production. MP Materials, USA Rare Earth, and TMC are three rare-earth stocks that have caught investors' …

465,000 Shares in USA Rare Earth Inc. $USAR Acquired by Encompass Capital Advisors LLC

Encompass Capital Advisors LLC recently acquired 465,000 shares of USA Rare Earth Inc. (NASDAQ:USAR) for approximately $7.04 million, representing a 0.21% stake in the company. Several other hedge funds also adjusted their positions in USAR. Despite the stock opening at $14.93, significantly below its …

Ultragenyx Q2 Results: Conference Call Scheduled for Aug 4

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is set to host a conference call on August 4, 2026, at 5:00 p.m. ET to discuss its second-quarter 2026 financial results and provide a corporate update. The biopharmaceutical company, specializing in rare genetic diseases, will make the call …

Ultragenyx Will Webcast Its August 4 Corporate Update

Ultragenyx (NASDAQ: RARE) announced it will host a conference call on Tuesday, August 4, 2026, at 5:00 p.m. ET to discuss its financial results and corporate update for the quarter ended June 30, 2026. A live and replayed webcast will be available on the …

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced it will host a conference call on Tuesday, August 4, 2026, at 5:00 p.m. ET. The call will cover the company's financial results and a corporate update for the quarter ending June 30, 2026. A webcast of the …

Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline

Ultragenyx (RARE) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to …

This ETF Was Built to Break China’s Rare Earth Grip. Trade or Trap?

Quick Read MP Materials holds a DoD-backed $110/kg NdPr price floor but still trades 33% below year-ago levels near $43. USAR dropped 34% in a single month despite closing $1.5 billion in PIPE financing, while NioCorp trades around $4, down 60% over five years. …

US backs Madagascar rare earths project with $4.84M to chip away at China's mineral dominance

[DEFM14A] USA Rare Earth, Inc. Merger Proxy Statement

USA Rare Earth, Inc. (USAR) has filed a definitive merger proxy statement (DEFM14A) asking stockholders to approve a share issuance for its proposed merger with SVRE Holdings Ltd. Stockholders are asked to vote on issuing 126,849,307 shares of common stock to SVRE securityholders and …

Ultragenyx Pharmaceutical, Inc. Revenue Breakdown – BIVA:RARE

Ultragenyx Pharmaceutical, Inc. (RARE) generated 12.13 billion MXN in revenue last year, primarily from its Novel Products segment. North America was the largest contributing region. The company's revenue from Novel Products increased compared to the previous year.

American Rare Earths (ASX: ARR) Strengthens Halleck Creek Development Pathway Ahead of 2026 PFS

Ultragenyx Pharmaceutical Inc (RARE) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Ultragenyx Pharmaceutical Inc (RARE) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays Ultragenyx Pharmaceutical's current stock price, market capitalization, and …

Lynas Rare Earths Stock And 2 Australian Miners With Strong Growth Outlook

RARE|Ultragenyx Pharmaceutical Inc|Price:26.900|Chg%:-0.120

This article provides a financial overview of Ultragenyx Pharmaceutical Inc. (RARE), detailing its stock performance, key financial indicators, and historical data from income statements, balance sheets, and cash flow statements up to FY2025. It highlights the company's revenue, EPS, net profit, assets, liabilities, and …

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. announced the grant of 65,886 restricted stock units to 39 newly hired non-executive officers. These grants were made under the company's Employment Inducement Plan on July 16, 2026, as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). …

Ultragenyx New Hires Get Stock Awards, 25% Vests Yearly

Ultragenyx (NASDAQ: RARE) has granted 65,886 restricted stock units (RSUs) to 39 new non-executive officers under its Employment Inducement Plan. These RSUs, granted on July 16, 2026, will vest over four years at 25% annually, contingent on continued employment. This action aligns with Nasdaq …

USA Rare Earth (USAR) Strengthens Its Mine-to-Magnet Strategy With Serra Verde Acquisition

USA Rare Earth, Inc. (USAR) is highlighted in Artisan Small Cap Fund’s Q2 2026 investor letter for its strategic acquisition of Serra Verde. This move is expected to bolster USAR's integrated mine-to-magnet platform, providing access to heavy rare earth production outside China and positioning …

Ultragenyx Pharmaceutical Inc (RARE) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Ultragenyx Pharmaceutical Inc (RARE), noting its current valuation score of 9.19 within the Pharmaceuticals industry. The P/E ratio is reported as -4.41, which is below its recent high and above its recent low. Key valuation metrics like …

Heavy Rare Earths Targets a Critical-Minerals Opportunity at Subron

USA Rare Earth (USAR) Stock Could Still Be A Bargain Despite A Rare Earth Processing Deal

Meta Title: Heavy Rare Earths (ASX:HRE) Falls 16% as Critical Minerals Explorer Extends Annual Decline to 29%

Lynas Rare Earths (ASX:LYC) Falls Despite 70% Revenue Growth as Production Concerns Persist